Loading...
01/10 16:57
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: positive growth in medical and AI sectors, strategic cash management, and shareholder returns. However, concerns arise from cash outflow, AC&C sector challenges, and semi-cap market uncertainties due to China restrictions. The Q&A highlights optimism in future growth but lacks detailed guidance. Given the market cap of $1.4 billion, these mixed factors suggest a neutral stock price movement within the -2% to 2% range over the next two weeks.
Revenue $642 million, up 2% sequentially and flat year-over-year. Reasons for change: Sequential growth driven by sector-specific performance, while year-over-year flatness reflects broader market conditions.
Non-GAAP EPS $0.55, at the midpoint of prior guidance. Reasons for change: Consistent execution and operational efficiency.
Non-GAAP Gross Margin 10.2%, up 10 basis points sequentially and flat year-over-year. Reasons for change: Improved operational efficiency and consistent performance.
Non-GAAP Operating Margin 4.7%, up 10 basis points sequentially. Reasons for change: Improvement in gross margin.
Semi-cap Revenue Decreased 2% quarter-over-quarter but grew 11% year-over-year. Reasons for change: Year-over-year growth driven by ramping wins and share gains, while quarter-over-quarter decline reflects broader industry recovery challenges.
Industrial Revenue Up 4% quarter-over-quarter and flat year-over-year. Reasons for change: Sequential growth driven by improvements in test & measurement and controls.
A&D Revenue Up 4% quarter-over-quarter and 16% year-over-year. Reasons for change: Strong demand in commercial air and defense, along with momentum in satellite and space applications.
Medical Revenue Up 6% quarter-over-quarter and down low-single-digits year-over-year. Reasons for change: Sequential growth due to overcoming customer inventory challenges, while year-over-year decline reflects prior inventory-related issues.
AC&C Revenue Flat quarter-over-quarter and down considerably year-over-year. Reasons for change: Impacted by unique dynamics in the sector, with expectations for recovery later in 2025.
Cash Balance $265 million as of June 30, a decrease of $90 million from Q1. Reasons for change: Impacted by one-time events related to customs and transition tax payments, working capital items, and capital expenditures.
Free Cash Flow $15 million outflow during the quarter. Reasons for change: Driven by one-time events and working capital adjustments.
Repatriated Cash $152 million from China and Thailand, with $95 million used to pay down revolver debt. Reasons for change: Strategic financial management and debt reduction.
Capital Expenditures $12 million during the quarter. Reasons for change: Investments in capabilities and infrastructure at Americas and Asia facilities.
Shareholder Returns $6 million in cash dividends and $8 million in stock repurchases. Reasons for change: Commitment to returning value to shareholders.
Cash Conversion Cycle 85 days, improving 1 day sequentially and 5 days year-over-year. Reasons for change: Active inventory management.
Medical bookings: Strong set of medical bookings across both manufacturing and engineering, including a competitive lift and shift takeaway program.
AI data center builds: Winning in AI data center builds leveraging complex assembly capabilities and water-cooling expertise.
Intel's Aurora exascale supercomputer deployment: Trusted partner for Intel's Aurora exascale supercomputer deployment due to water cooling expertise.
Semi-cap sector: Double-digit year-over-year growth driven by ramping wins and share gains. Mid- to long-term trends support ongoing investments.
Industrial sector: Sequential growth expected throughout the year as end markets recover and new programs ramp.
A&D sector: Strong double-digit year-over-year revenue growth with stable commercial air environment and strong defense demand. Growing momentum in satellite and space applications.
AC&C sector: Anticipated return to growth later in 2025 and into 2026, driven by opportunities in compute and AI data center builds.
Debt refinancing: Successfully refinanced debt at attractive rates, extending maturity to June 2030.
Cash repatriation: Repatriated $152 million from China and Thailand, using $95 million to pay down revolver.
Capital expenditures: Invested $12 million to enhance capabilities and infrastructure in Americas and Asia facilities.
Customer program awards: Current customers awarding more programs, reflecting strong operational performance.
Market positioning: Leveraging globally diversified manufacturing footprint to offer flexibility in tariff and supply chain optimization.
Semi-cap sector: Continued trade restrictions and tariff uncertainties are delaying broader industry recovery, leading to expected softness in this sector for the foreseeable future.
Cash flow and liquidity: Temporary pause in free cash flow generation due to one-time events related to customs and transition tax payments. Liquidity ratio has decreased significantly from 0.7 to 0.3 year-over-year.
AC&C sector: Revenue has been down year-over-year and flat sequentially due to unique dynamics. Growth is not expected until late 2025 or 2026.
Inventory management: Customer inventory-related challenges have impacted growth in the Medical sector over the last several quarters, though these issues are reportedly resolved now.
Debt refinancing: While the company successfully refinanced its debt, the increase in the term loan to $150 million and the outstanding revolver debt of $60 million could pose financial risks if not managed effectively.
Economic uncertainties: Dynamic macro environment continues to pose challenges, requiring prudent spending management to protect profitability and free cash flow.
Revenue Expectations: Revenue for Q3 2025 is expected to be in the range of $635 million to $685 million, representing low-single-digit sequential growth. Year-over-year growth of low- to mid-single digits is anticipated for the second half of 2025.
Gross Margin Projections: Non-GAAP gross margin for Q3 2025 is expected to be between 10.2% and 10.4%. The company expects to maintain non-GAAP gross margins of 10% or more.
Operating Margin Projections: Non-GAAP operating margin for Q3 2025 is projected to be between 5% and 5.2%.
Earnings Per Share (EPS) Guidance: Non-GAAP diluted EPS for Q3 2025 is expected to range from $0.56 to $0.62.
Tax Rate: The effective tax rate for Q3 2025 is expected to be between 23% and 25%.
Sector-Specific Outlook: - Semi-cap: Continued softness expected in Q3 and the second half of 2025, but the company anticipates outperforming the overall market's growth rate. Long-term secular trends remain positive, with expectations of a $1 trillion semi-cap industry by 2030.
Capital Expenditures: Approximately $12 million invested in Q2 2025 to enhance capabilities and infrastructure, supporting long-term growth and operational efficiency.
Free Cash Flow: The company expects to return to positive free cash flow for the remainder of 2025.
Cash Dividends: We returned $6 million in cash dividends during the quarter.
Stock Repurchase: We repurchased $8 million in stock during the quarter.
Remaining Share Repurchase Authorization: At the end of the quarter, we had approximately $134 million remaining in our existing share repurchase authorization.
The earnings call shows strong financial results with revenue and EPS at the high end of guidance, positive free cash flow, and significant shareholder returns through dividends and share repurchases. The Q&A section highlights optimism in sectors like AI and A&D, despite some uncertainties in semi-cap. The company's positive outlook for 2026, coupled with strategic investments, suggests a positive market reaction. Given the small-cap nature, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
The earnings call reveals mixed signals: positive growth in medical and AI sectors, strategic cash management, and shareholder returns. However, concerns arise from cash outflow, AC&C sector challenges, and semi-cap market uncertainties due to China restrictions. The Q&A highlights optimism in future growth but lacks detailed guidance. Given the market cap of $1.4 billion, these mixed factors suggest a neutral stock price movement within the -2% to 2% range over the next two weeks.
The earnings call presents a mixed picture: while revenue declined YoY and recession risks loom, the company maintained EPS guidance, improved cash flow, and executed share repurchases. The Q&A highlights balanced customer sentiment and potential growth in medical and automation sectors. Despite headwinds from tariffs and a customs audit, the company shows resilience. The stock market cap suggests moderate sensitivity. Overall, the sentiment is neutral, with no strong catalysts for a significant stock price change in the next two weeks.
The earnings call presents a mixed picture: a decline in revenue and liquidity challenges are offset by strong EPS, cash flow, and share repurchases. Q&A insights reveal cautious optimism with growth expected in the second half, particularly in medical and compute sectors. However, concerns about customer hesitancy and China-related order softening persist. Given these factors and the company's small-cap status, the stock price is likely to remain stable, leading to a neutral prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
